Screener
Aurinia Pharmaceuticals AUPH Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Aurinia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: Aurinia Pharmaceuticals’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 8:16 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001600620-26-000062
FAQ
- What is Aurinia Pharmaceuticals's cash & equivalents?
- Aurinia Pharmaceuticals (AUPH) reported cash & equivalents of $179.83M in Q2 2026.
- How has Aurinia Pharmaceuticals's cash & equivalents changed year-over-year?
- Aurinia Pharmaceuticals's cash & equivalents increased by 239.3% year-over-year, from $53M to $179.83M.
- What is the long-term trend for Aurinia Pharmaceuticals's cash & equivalents?
- Over 5 years (2020 to 2025), Aurinia Pharmaceuticals's cash & equivalents has grown at a -21.7% compound annual growth rate (CAGR), from $272.35M to $80.21M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Aurinia Pharmaceuticals's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude